{"id":52605,"date":"2023-01-05T21:03:28","date_gmt":"2023-01-05T20:03:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/crown-bioscience-publishes-new-study-in-plos-one-highlighting-the-use-of-clinically-relevant-3d-in-vitro-pdx-derived-organoid-models-as-powerful-tools-to-accelerate-cancer-drug-discovery\/"},"modified":"2023-01-05T21:03:28","modified_gmt":"2023-01-05T20:03:28","slug":"crown-bioscience-publishes-new-study-in-plos-one-highlighting-the-use-of-clinically-relevant-3d-in-vitro-pdx-derived-organoid-models-as-powerful-tools-to-accelerate-cancer-drug-discovery","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/crown-bioscience-publishes-new-study-in-plos-one-highlighting-the-use-of-clinically-relevant-3d-in-vitro-pdx-derived-organoid-models-as-powerful-tools-to-accelerate-cancer-drug-discovery\/","title":{"rendered":"Crown Bioscience Publishes New Study in PLOS ONE Highlighting the Use of Clinically Relevant 3D In Vitro PDX-Derived Organoid Models as Powerful Tools to Accelerate Cancer Drug Discovery"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience, a global contract research organization (CRO), and JSR Life Sciences company, announced today their newly published study in PLOS ONE<\/i>, a journal of the Public Library of Science (PLOS), demonstrating the establishment and application of a highly clinically relevant 3D in vitro<\/i> PDX-derived organoid (PDXO) biobank for higher-throughput screening for cancer drug discovery.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThis study aligns well with the recent Senate Bill 5002, titled FDA Modernization Act 2.0, introduced in the United States Senate, which authorizes the use of alternatives to animal testing, including cell-based assays for the purposes of drug and biological product applications.\n<\/p>\n

\n\u201cThis invaluable publication demonstrates our ongoing commitment to develop innovative preclinical models for our customers by including the provision of robust and clinically relevant in vitro<\/i> solutions as early as possible in the drug development process followed with matched translational models downstream,\u201d commented Rajendra Kumari, PhD, Executive Director of Integrated Solutions at Crown Bioscience.<\/b> \u201cOrganoids maintain a high degree of clinical relevance that cannot be achieved with traditional 2D cell lines and other 3D systems. As a result, in vitro<\/i> drug screening with PDXOs represents a highly physiologically relevant platform that better predicts patient response making these ideal alternatives to animal testing.\u201d\n<\/p>\n

\nThis new study reports on the largest living, commercially available PDXO biobank\u2014with approximately 550 tumor organoid models derived from a collection of matched PDXs representing 17 different types of carcinomas. The main findings of the study include:\n<\/p>\n